Using Therapeutic Drug Monitoring to Treat KPC-Producing Klebsiella pneumoniae Central Nervous System Infection With Ceftazidime/Avibactam.
Loading...
Issue Date
2020-09
Authors
Yasmin, Mohamad
Hanrahan, Jennifer
Marshall, Steven H
Lodise, Thomas P
Chen, Liang
Perez, Federico
Kreiswirth, Barry
Bonomo, Robert A
Degree
Advisor
Committee Members
Journal Title
Journal ISSN
Volume Title
Abstract
This report describes the treatment of Klebsiella pneumoniae carbapenemase (KPC)-3-producing multidrug-resistant K. pneumoniae with ceftazidime/avibactam (CAZ-AVI) in a patient who developed postneurosurgical meningitis and bacteremia. Therapeutic drug monitoring of cerebrospinal fluid and blood samples demonstrated CAZ-AVI concentration levels 20-fold greater than the minimum inhibitory concentration in the first 60 minutes postinfusion, providing evidence for the utility of CAZ-AVI in treating KPC-Klebsiella pneumoniae central nervous system infections.
Citation
Yasmin M, Hanrahan J, Marshall S, Lodise TP, Chen L, Perez F, Kreiswirth B, Bonomo RA. Using Therapeutic Drug Monitoring to Treat KPC-Producing Klebsiella pneumoniae Central Nervous System Infection With Ceftazidime/Avibactam. Open Forum Infect Dis. 2020 Aug 18;7(9):ofaa349. doi: 10.1093/ofid/ofaa349. PMID: 32964066; PMCID: PMC7491706.
ACPHS Research Commons URI
Description
Grants
R01 AI100560/AI/NIAID NIH HHS/United States , R01 AI072219/AI/NIAID NIH HHS/United States , R01 AI063517/AI/NIAID NIH HHS/United States , I01 BX001974/BX/BLRD VA/United States , I01 BX005307/BX/BLRD VA/United States , R01 AI090155/AI/NIAID NIH HHS/United States